A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (Morpheus-Gastric Cancer)

Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (Morpheus-Gastric Cancer)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Atezolizumab (Primary) ; BL 8040 (Primary) ; Cobimetinib (Primary) ; Hyaluronidase (Primary) ; Linagliptin (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel; Ramucirumab
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms UMBRELLA
  • Sponsors Roche
  • Most Recent Events

    • 18 Oct 2017 Status changed from not yet recruiting to recruiting, according to a BioLineRx media release.
    • 15 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top